CCO Annual Update
HIV/AIDS Annual Update 2003
Immune Control and Immune Failure in HIV Infection |
Module 1 of 8 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Immune Control of Chronic Viral Infections
- Innate Immunity in HIV Infection
- Adaptive Immunity in HIV Infection
- Dissecting the Causes of Immune Failure in HIV Infection
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the effects of antiretroviral therapy on immune reconstitution. Discuss the role of immune-based therapy in the management of HIV infection Describe the mechanisms of immune impairment in HIV infection
|
Viral Pathogenesis: Clinical Implications of HIV-1 Latent Reservoirs |
Module 2 of 8 |
|
Program Director: John P. Phair, MD
- Robert F. Siliciano, MD, PhD
|
|
|
Topics covered include:
- Introduction
- Definition of Viral Reservoirs
- Establishment of a Reservoir of Latently Infected Resting Memory CD4+ T Cells
- Stability of the Reservoir of Resting CD4+ T Cells
- Clinical Implications of the Latent Reservoir
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the nature of the low-level viremia that persists in patients on HAART. Describe the concept of the archive as a stable reservoir for archival wild-type and drug resistant viruses. Review the origin of the latent reservoir for HIV and its relationship to immunologic memory.
|
Treatment of Antiretroviral-Naive Patients |
Module 3 of 8 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- When to Start
- What to Start With
- PIs + 2 NRTIs
- NNRTI + 2 NRTIs
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the management of treatment intolerance and initial failure Review the options for initial antiretroviral therapy Discuss when to start antiretroviral therapy
|
HIV-1 Drug Resistance: from Mechanisms to Management |
Module 4 of 8 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Mechanisms of Antiretroviral Drug Resistance
- Paths to Resistance: Two Viruses Diverged in an Evolutionary Wood...
- Testing for Drug Resistance
- Guidelines for Drug Resistance Testing
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss recent developments in the molecular basis of antiretroviral drug resistance and their impact on clinical management. Describe and contrast measures of drug resistance and viral replication capacity. Review the management of patients who have conflicting results from genotyping and phenotyping.
|
Novel Antiretroviral Agents |
Module 5 of 8 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Nucleoside/Nucleotide Analogue Reverse Transcriptase Inhibitors
- Nonnucleoside Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Protease Inhibitors (Cont.)
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe steps in the HIV life cycle that offer targets for new antiretroviral agents. List reasons why new antiretroviral agents are needed for existing targets, and examples of such agents. Evaluate new targets such as HIV entry and integrase, prospective agents, and their potential positioning in HIV therapy.
|
Management of Hepatitis Virus Coinfection in HIV-Infected Patients |
Module 6 of 8 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Hepatitis B: Epidemiology, Diagnosis, and Pathogenesis
- Hepatitis B: Treatment and Prevention
- Hepatitis C: Epidemiology, Diagnosis, and Pathogenesis
- Management of Hepatitis C
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss indications for treatment of hepatitis C. Review current treatment approaches for hepatitis in HIV/HCV-coinfected patients. Describe diagnosis and screening for hepatitis B and C.
|
HIV-Associated Lipodystrophy: Mechanisms and Management |
Module 7 of 8 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Definition of Lipodystrophy
- Etiology and Pathogenesis
- Treatment of Lipodystrophy
- Alterations in Glucose Metabolism
Learning Objectives
Upon completion of this activity, participants should be able to:
Assess the consequences of lipodystrophy in context. Delineate the major unanswered questions regarding the management of lipodystrophy. Discuss an evidence-based approach to the management of lipodystrophy. Describe the hypotheses underlying the pathogenesis of lipodystrophy.
|
HIV Infection in Women: An Update |
Module 8 of 8 |
|
Program Director: John P. Phair, MD
- Judith S. Currier, MD, MSc
|
|
|
Topics covered include:
- Introduction
- Epidemiology
- Natural History of HIV Disease in Women
- Treatment of HIV-Infected Women: Outcomes
- Antiretroviral Pharmacology and Toxicities
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the natural history of HIV infection in women. Cite the demographic features of HIV-infected women. Differentiate the use and toxicities of antiretroviral therapy in women vs men. Discuss the optimal management of the HIV-infected woman, in terms of her own case, and prevention of vertical transmission.
|
Animations
The Role of Integrase in HIV Replication
 |
|
This animation and others are available for use offline from the Download Library.
To download to your own computer and use for personal or teaching purposes, click here
Format: Adobe Flash (.swf) |
File size: 1.57 MB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|